Natera NTRA underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 8 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 3 | 4 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $167.71, a high estimate of $200.00, and a low estimate of $135.00. Observing a 18.41% increase, the current average has risen from the previous average price target of $141.64.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Natera. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eve Burstein | Bernstein | Raises | Outperform | $200.00 | $160.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $180.00 | $165.00 |
| Julia Qin | JP Morgan | Raises | Overweight | $200.00 | $160.00 |
| David Westenberg | Piper Sandler | Raises | Overweight | $200.00 | $150.00 |
| Tejas Savant | Morgan Stanley | Raises | Overweight | $176.00 | $132.00 |
| Dan Brennan | TD Cowen | Raises | Buy | $175.00 | $155.00 |
| Alexander Nowak | Craig-Hallum | Raises | Buy | $157.00 | $121.00 |
| Julia Qin | JP Morgan | Raises | Overweight | $160.00 | $135.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $165.00 | $150.00 |
| Catherine Ramsey | Baird | Raises | Outperform | $160.00 | $120.00 |
| Eve Burstein | Bernstein | Raises | Outperform | $135.00 | $125.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $150.00 | $145.00 |
| Puneet Souda | Leerink Partners | Raises | Outperform | $150.00 | $140.00 |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $140.00 | $125.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Natera's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Natera's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Natera analyst ratings.
Get to Know Natera Better
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera: Delving into Financials
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Natera displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 63.9%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Natera's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.18% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Natera's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Natera's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.54, Natera faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
